Psychopharmacological interventions in autism spectrum disorder

References

• American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington, VA: American Psychiatric Publishing. Text citation: (American Psychiatric Association, 2013); 2013.
   Google Scholar
• Centers for Disease Control and Prevention. Prevalence of autism spectrum disorder among children aged 8 years—Autism and developmental disabilities monitoring network, 11 Sites, United States, 2010. MMWR Surveill Summ. 2014:63(2):1–22.
   Web of Science ®Google Scholar
• Reichow B, Barton EE, Boyd BA, et al. Early intensive behavioral intervention (EIBI) for young children with autism spectrum disorders (ASD). Cochrane Database Syst Rev. 2012;10:CD009260.
   PubMedGoogle Scholar
• Joshi G, Petty C, Wozniak J, et al. The heavy burden of psychiatric comorbidity in youth with autism spectrum disorders: a large comparative study of a psychiatrically referred population. J Autism Dev Disord. 2010;40:1361–1370.
   PubMed Web of Science ®Google Scholar
• Peacock G, Amendah D, Ouyang L, et al. Autism spectrum disorders and health care expenditures: the effects of co-occurring conditions. J Dev Behav Pediatr. 2012;33:2–8.
   PubMed Web of Science ®Google Scholar
• Coury DL, Anagnostou E, Manning-Courtney P, et al. Use of psychotropic medication in children and adolescents with autism spectrum disorders. Pediatrics. 2012;130(suppl 2):S69–76.
   PubMedGoogle Scholar
• Mazefsky CA, Conner CM, Oswald DP. Association between depression and anxiety in high-functioning children with autism spectrum disorders and maternal mood symptoms. Autism Res. 2010;3:120–127.
   PubMed Web of Science ®Google Scholar
• Mazefsky CA, Folstein SE, Lainhart JE. Overrepresentation of mood and anxiety disorders in adults with autism and their first-degree relatives: what does it mean? Autism Res. 2008;1:193–197.
   PubMed Web of Science ®Google Scholar
• Strang JF, Kenworthy L, Daniolos P, et al. Depression and anxiety symptoms in children and adolescents with autism spectrum disorders without intellectual disability. Res Autism Spectr Disord. 2012;6:406–412.
   PubMed Web of Science ®Google Scholar
• Andersen IM, Kaczmarska J, McGrew SG, et al. Melatonin for insomnia in children with autism spectrum disorders. J Child Neurol. 2008;23:482–485.
   PubMed Web of Science ®Google Scholar
• Cortesi F, Giannotti F, Sebastiani T, et al. Controlled-release melatonin, singly and combined with cognitive behavioural therapy, for persistent insomnia in children with autism spectrum disorders: a randomized placebo-controlled trial. J Sleep Res. 2012;21:700–709.
   PubMed Web of Science ®Google Scholar
• Garstang J, Wallis M. Randomized controlled trial of melatonin for children with autistic spectrum disorders and sleep problems. Child Care Health Dev. 2006;32:585–589.
   PubMed Web of Science ®Google Scholar
• Giannotti F, Cortesi F, Cerquiglini A, et al. An open-label study of controlled-release melatonin in treatment of sleep disorders in children with autism. J Autism Dev Disord. 2006;36:741–752.
   PubMed Web of Science ®Google Scholar
• Guenole F, Godbout R, Nicolas A, et al. Melatonin for disordered sleep in individuals with autism spectrum disorders: systematic review and discussion. Sleep Med Rev. 2011;15:379–387.
   PubMed Web of Science ®Google Scholar
• Malow B, Adkins KW, McGrew SG, et al. Melatonin for sleep in children with autism: a controlled trial examining dose, tolerability, and outcomes. J Autism Dev Disord. 2012;42:1729–37; author reply 1738.
   PubMed Web of Science ®Google Scholar
• Wasdell MB, Jan JE, Bomben MM, et al. A randomized, placebo-controlled trial of controlled release melatonin treatment of delayed sleep phase syndrome and impaired sleep maintenance in children with neurodevelopmental disabilities. J Pineal Res. 2008;44:57–64.
   PubMed Web of Science ®Google Scholar
• Wirojanan J, Jacquemont S, Diaz R, et al. The efficacy of melatonin for sleep problems in children with autism, fragile X syndrome, or autism and fragile X syndrome. J Clin Sleep Med. 2009;5:145–150.
   PubMed Web of Science ®Google Scholar
• Wright B, Sims D, Smart S, et al. Melatonin versus placebo in children with autism spectrum conditions and severe sleep problems not amenable to behaviour management strategies: a randomized controlled crossover trial. J Autism Dev Disord. 2011;41:175–184.
   PubMed Web of Science ®Google Scholar
• Bethea TC, Sikich L. Early pharmacological treatment of autism: a rationale for developmental treatment. Biol Psychiatry. 2007;61:521–537.
   PubMed Web of Science ®Google Scholar
• Kaat AJ, Lecavalier L, Aman MG. Validity of the aberrant behavior checklist in children with autism spectrum disorder. J Autism Dev Disord. 2014;44:1103–1116.
   PubMed Web of Science ®Google Scholar
• McCracken JT, McGough J, Shah B, et al. Risperidone in children with autism and serious behavioral problems. N Engl J Med. 2002;347:314–321.
   PubMed Web of Science ®Google Scholar
• Shea S, Turgay A, Carroll A, et al. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics. 2004;114:e634–41.
   PubMed Web of Science ®Google Scholar
• Pandina GJ, Bossie CA, Youssef E, et al. Risperidone improves behavioral symptoms in children with autism in a randomized, double-blind, placebo-controlled trial. J Autism Dev Disord. 2007;37:367–373.
   PubMed Web of Science ®Google Scholar
• McDougle CJ, Holmes JP, Carlson DC, et al. A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders. Arch Gen Psychiatry. 1998;55:633–41.
   PubMed Web of Science ®Google Scholar
• Malone RP, Maislin G, Choudhury MS, et al. Risperidone treatment in children and adolescents with autism: short- and long-term safety and effectiveness. J Am Acad Child Adolesc Psychiatry. 2002;41:140–147.
   PubMed Web of Science ®Google Scholar
• Nagaraj R, Singhi P, Malhi P. Risperidone in children with autism: randomized, placebo-controlled, double-blind study. J Child Neurol. 2006;21:450–455.
   PubMed Web of Science ®Google Scholar
• Troost PW, Lahuis BE, Steenhuis MP, et al. Long-term effects of risperidone in children with autism spectrum disorders: a placebo discontinuation study. J Am Acad Child Adolesc Psychiatry. 2005;44:1137–1144.
   PubMed Web of Science ®Google Scholar
• Aman MG, McDougle CJ, Scahill L, et al. Medication and parent training in children with pervasive developmental disorders and serious behavior problems: results from a randomized clinical trial. J Am Acad Child Adolesc Psychiatry. 2009;48:1143–1154.
   PubMed Web of Science ®Google Scholar
• Aman MG, Arnold LE, McDougle CJ, et al. Acute and long-term safety and tolerability of risperidone in children with autism. J Child Adolesc Psychopharmacol. 2005;15:869–884.
   PubMed Web of Science ®Google Scholar
• Martin A, Scahill L, Anderson GM, et al. Weight and leptin changes among risperidone-treated youths with autism: 6-month prospective data. Am J Psychiatry. 2004;161:1125–1127.
   PubMed Web of Science ®Google Scholar
• Anderson GM, Scahill L, McCracken JT, et al. Effects of short- and long-term risperidone treatment on prolactin levels in children with autism. Biol Psychiatry. 2007;61:545–550.
   PubMed Web of Science ®Google Scholar
• Marcus RN, Owen R, Kamen L, et al. A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. J Am Acad Child Adolesc Psychiatry. 2009;48:1110–1119.
   PubMed Web of Science ®Google Scholar
• Owen R, Sikich L, Marcus RN, et al. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics. 2009;124:1533–40.
   PubMed Web of Science ®Google Scholar
• Aman MG, Kasper W, Manos G, et al. Line-item analysis of the aberrant behavior checklist: results from two studies of aripiprazole in the treatment of irritability associated with autistic disorder. J Child Adolesc Psychopharmacol. 2010;20:415–422.
   PubMed Web of Science ®Google Scholar
• Marcus RN, Owen R, Manos G, et al. Safety and tolerability of aripiprazole for irritability in pediatric patients with autistic disorder: a 52-week, open-label, multicenter study. J Clin Psychiatry. 2011;72:1270–1276.
   PubMed Web of Science ®Google Scholar
• Ho JG, Caldwell RL, McDougle CJ, et al. The effects of aripiprazole on electrocardiography in children with pervasive developmental disorders. J Child Adolesc Psychopharmacol. 2012;22:277–283.
   PubMed Web of Science ®Google Scholar
• Malone RP, Cater J, Sheikh RM, et al. Olanzapine versus haloperidol in children with autistic disorder: an open pilot study. J Am Acad Child Adolesc Psychiatry. 2001;40:887–894.
   PubMed Web of Science ®Google Scholar
• Potenza MN, Holmes JP, Kanes SJ, et al. Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: an open-label pilot study. J Clin Psychopharmacol. 1999;19:37–44.
   PubMed Web of Science ®Google Scholar
• Fido A, Al-Saad S. Olanzapine in the treatment of behavioral problems associated with autism: an open-label trial in Kuwait. Med Princ Pract. 2008;17:415–418.
   PubMed Web of Science ®Google Scholar
• Kemner C, Willemsen-Swinkels SH, de Jonge M, et al. Open-label study of olanzapine in children with pervasive developmental disorder. J Clin Psychopharmacol. 2002;22:455–460.
   PubMed Web of Science ®Google Scholar
• Findling RL, McNamara NK, Gracious BL, et al. Quetiapine in nine youths with autistic disorder. J Child Adolesc Psychopharmacol. 2004;14:287–294.
   PubMed Web of Science ®Google Scholar
• Martin A, Koenig K, Scahill L, et al. Open-label quetiapine in the treatment of children and adolescents with autistic disorder. J Child Adolesc Psychopharmacol. 1999;9:99–107.
   PubMed Web of Science ®Google Scholar
• Golubchik P, Sever J, Weizman A. Low-dose quetiapine for adolescents with autistic spectrum disorder and aggressive behavior: open-label trial. Clin Neuropharmacol. 2011;34:216–219.
   PubMed Web of Science ®Google Scholar
• Duggal HS. Ziprasidone for maladaptive behavior and attention-deficit/hyperactivity disorder symptoms in autistic disorder. J Child Adolesc Psychopharmacol. 2007;17:261–263.
   PubMed Web of Science ®Google Scholar
• Goforth HW, Rao MS. Improvement in behaviour and attention in an autistic patient treated with ziprasidone. Aust N Z J Psychiatry. 2003;37:775–776.
   PubMed Web of Science ®Google Scholar
• Malone RP, Delaney MA, Hyman SB, et al. Ziprasidone in adolescents with autism: an open-label pilot study. J Child Adolesc Psychopharmacol. 2007;17:779–790.
   PubMed Web of Science ®Google Scholar
• McDougle CJ, Kem DL, Posey DJ. Case series: use of ziprasidone for maladaptive symptoms in youths with autism. J Am Acad Child Adolesc Psychiatry. 2002;41:921–927.
   PubMed Web of Science ®Google Scholar
• Ghanizadeh A, Sahraeizadeh A, Berk M. A head-to-head comparison of aripiprazole and risperdione for safety and treating autistic disorders, a randomized double blind clinical trial. Child Psychiatry Hum Dev. 2014;45:185–192.
   PubMed Web of Science ®Google Scholar
• Pringsheim T, Panagiotopoulos C, Davidson J, et al. Evidence-based recommendations for monitoring safety of second generation antipsychotics in children and youth. J Can Acad Child Adolesc Psychiatry. 2011;20(3):218–233.
   PubMedGoogle Scholar
• Anagnostou E, Esposito K, Soorya L, et al. Divalproex versus placebo for the prevention of irritability associated with fluoxetine treatment in autism spectrum disorder. J Clin Psychopharmacol. 2006;26:444–446.
   PubMed Web of Science ®Google Scholar
• Childs JA, Blair JL. Valproic acid treatment of epilepsy in autistic twins. J Neurosci Nurs. 1997;29:244–248.
   PubMedGoogle Scholar
• Plioplys AV. Autism: electroencephalogram abnormalities and clinical improvement with valproic acid. Arch Pediatr Adolesc Med. 1994;148:220–222.
   PubMedGoogle Scholar
• Hollander E, Dolgoff-Kaspar R, Cartwright C, et al. An open trial of divalproex sodium in autism spectrum disorders. J Clin Psychiatry. 2001;62:530–534.
   PubMed Web of Science ®Google Scholar
• Hellings JA, Weckbaugh M, Nickel EJ, et al. A double-blind, placebo-controlled study of valproate for aggression in youth with pervasive developmental disorders. J Child Adolesc Psychopharmacol. 2005;15:682–692.
   PubMed Web of Science ®Google Scholar
• Hollander E, Chaplin W, Soorya L, et al. Divalproex sodium vs placebo for the treatment of irritability in children and adolescents with autism spectrum disorders. Neuropsychopharmacology. 2010;35:990–998.
   PubMed Web of Science ®Google Scholar
• Belsito KM, Law PA, Kirk KS, et al. Lamotrigine therapy for autistic disorder: a randomized, double-blind, placebo-controlled trial. J Autism Dev Disord. 2001;31:175–81.
   PubMed Web of Science ®Google Scholar
• Wasserman S, Iyengar R, Chaplin WF, et al. Levetiracetam versus placebo in childhood and adolescent autism: a double-blind placebo-controlled study. Int Clin Psychopharmacol. 2006;21:363–367.
   PubMed Web of Science ®Google Scholar
• Rugino TA, Samsock TC. Levetiracetam in autistic children: an open-label study. J Dev Behav Pediatr. 2002;23:225–230.
   PubMed Web of Science ®Google Scholar
• Kapetanovic S. Oxcarbazepine in youths with autistic disorder and significant disruptive behaviors. Am J Psychiatry. 2007;164:832–833.
   PubMed Web of Science ®Google Scholar
• Douglas JF, Sanders KB, Benneyworth MH, et al. Brief report: retrospective case series of oxcarbazepine for irritability/agitation symptoms in autism spectrum disorder. J Autism Dev Disord. 2013;43:1243–1247.
   PubMed Web of Science ®Google Scholar
• Hardan AY, Jou RJ, Handen BL. A retrospective assessment of topiramate in children and adolescents with pervasive developmental disorders. J Child Adolesc Psychopharmacol. 2004;14:426–432.
   PubMed Web of Science ®Google Scholar
• Mazzone L, Ruta L. Topiramate in children with autistic spectrum disorders. Brain Dev. 2006;28:668.
   PubMed Web of Science ®Google Scholar
• Canitano R. Clinical experience with topiramate to counteract neuroleptic induced weight gain in 10 individuals with autistic spectrum disorders. Brain Dev. 2005;27:228–232.
   PubMed Web of Science ®Google Scholar
• Serret S, Thümmler S, Dor E, et al. Lithium as a rescue therapy for regression and catatonia features in two SHANK3 patients with autism spectrum disorder: case reports. BMC Psychiatry. 2015;15:107.
   PubMed Web of Science ®Google Scholar
• Siegel M, Beresford CA, Bunker M, et al. Preliminary investigation of lithium for mood disorder symptoms in children and adolescents with autism spectrum disorder. J Child Adol Psychopharm. 2014;24(7):399–402.
   PubMed Web of Science ®Google Scholar
• Ghaleiha A, Asadabadi M, Mohammadi MR, et al. Memantine as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind, placebo-controlled trial. Int Neuropsychopharm. 2013;16:783–789.
   PubMed Web of Science ®Google Scholar
• Erickson CA, Veenstra-vanderweele JM, Melmed RD, et al. STX209 (arbaclofen) for autism spectrum disorders: an 8-week open-label study. J Autism Dev Disord. 2014;44(4):958–964.
   PubMed Web of Science ®Google Scholar
• Berk M, Copolov D, Dean O, et al. N-acetyl cysteine as a glutathione precursor for schizophrenia—a double-blind, randomized, placebo-controlled trial. Biol Psychiatry. 2008;64:361–368.
   PubMed Web of Science ®Google Scholar
• Berk M, Copolov DL, Dean O, et al. N-acetyl cysteine for depressive symptoms in bipolar disorder—a double-blind randomized placebo-controlled trial. Biol Psychiatry. 2008;64:468–475.
   PubMed Web of Science ®Google Scholar
• Berk M, Dean O, Cotton SM, et al. The efficacy of N-acetylcysteine as an adjunctive treatment in bipolar depression: an open label trial. J Affect Disord. 2011;135:389–394.
   PubMed Web of Science ®Google Scholar
• Grant JE, Kim SW, Odlaug BL. N-acetyl cysteine, a glutamate-modulating agent, in the treatment of pathological gambling: a pilot study. Biol Psychiatry. 2007;62:652–657.
   PubMed Web of Science ®Google Scholar
• Lafleur DL, Pittenger C, Kelmendi B, et al. N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder. Psychopharmacology (Berl). 2006;184:254–256.
   PubMed Web of Science ®Google Scholar
• Magalhaes PV, Dean OM, Bush AI, et al. N-acetylcysteine for major depressive episodes in bipolar disorder. Rev Bras Psiquiatr. 2011;33:374–378.
   PubMed Web of Science ®Google Scholar
• Hardan AY, Fung LK, Libove RA, et al. A randomized controlled pilot trial of oral N-acetylcysteine in children with autism. Biol Psychiatry. 2012;71:956–961.
   PubMed Web of Science ®Google Scholar
• Singh K, Connors SL, Macklin EA, et al. Sulforaphane treatment of autism spectrum disorder (ASD). Proc Natl Acad Sci USA. 2014;111(43):15550–15555.
   PubMed Web of Science ®Google Scholar
• Symons FJ, Thompson A, Rodriguez MC. Self-injurious behavior and the efficacy of naltrexone treatment: a quantitative synthesis. Ment Retard Dev Disabil Res Rev. 2004;10(3):193–200.
   PubMedGoogle Scholar
• McDougle CJ, Kresch LE, Goodman WK, et al. A case controlled study of repetitive thoughts and behavior in adults with autistic disorder and obsessive-compulsive disorder. Am J of Psych. 1995;152:772–777.
   Web of Science ®Google Scholar
• Gordon CT, State RC, Nelson JE, et al.A double-blind comparison of clomipramine, desipramine, and placebo in the treatment of autistic disorder. Arch Gen Psychiatry. 1993;50:441–447.
   PubMed Web of Science ®Google Scholar
• Ghaziuddin M, Tsai L, Ghaziuddin N. Fluoxetine in autism with depression. J Am Acad Child Adolesc Psychiatry. 1991;30:508–509.
   PubMed Web of Science ®Google Scholar
• Alcami Pertejo M, Peral Guerra M, Gilaberte I. Open study of fluoxetine in children with autism. Actas Esp Psiquiatr. 2000;28:353–356.
   PubMed Web of Science ®Google Scholar
• Buchsbaum MS, Hollander E, Haznedar MM, et al. Effect of fluoxetine on regional cerebral metabolism in autistic spectrum disorders: a pilot study. Int J Neuropsychopharmacol. 2001;4:119–125.
   PubMed Web of Science ®Google Scholar
• DeLong GR, Ritch CR, Burch S. Fluoxetine response in children with autistic spectrum disorders: correlation with familial major affective disorder and intellectual achievement. Dev Med Child Neurol. 2002;44:652–9. Comment: Bates G, Willson SW. Use of selective serotonin reuptake inhibitors in children with pervasive developmental disorder: risk of treatment emergent mania. Dev Med Child Neurol 2003;45:359; author reply 360.
   PubMed Web of Science ®Google Scholar
• DeLong GR, Teague LA, McSwain Kamran M. Effects of fluoxetine treatment in young children with idiopathic autism. Dev Med Child Neurol. 1998;40:551–62. Comment: Bax M. A treatment that works. Dev Med Child Neurol 1998;40:507.
   PubMed Web of Science ®Google Scholar
• Hellings JA, Kelley LA, Gabrielli WF, et al. Sertraline response in adults with mental retardation and autistic disorder. J Clin Psychiatry. 1996;57:333–336.
   PubMed Web of Science ®Google Scholar
• McDougle CJ, Brodkin ES, Naylor ST, et al. Sertraline in adults with pervasive developmental disorders: a prospective open-label investigation. J Clin Psychopharmacol. 1998;18:62–66.
   PubMed Web of Science ®Google Scholar
• Namerow LB, Thomas P, Bostic JQ, et al. Use of citalopram in pervasive developmental disorders. J Dev Behav Pediatr. 2003;24:104–108.
   PubMed Web of Science ®Google Scholar
• Owley T, Walton L, Salt J, et al. An open-label trial of escitalopram in pervasive developmental disorders. J Am Acad Child Adolesc Psychiatry. 2005;44:343–348.
   PubMed Web of Science ®Google Scholar
• Desousa A. An open-label trial of risperidone and fluoxetine in children with autistic disorder. Indian J Psychol Med. 2010;32:17–21.
   PubMedGoogle Scholar
• Henry CA, Steingard R, Venter J, et al. Treatment outcome and outcome associations in children with pervasive developmental disorders treated with selective serotonin reuptake inhibitors: a chart review. J Child Adolesc Psychopharmacol. 2006;16:187–195.
   PubMed Web of Science ®Google Scholar
• Steingard RJ, Zimnitzky B, DeMaso DR, et al. Sertraline treatment of transition-associated anxiety and agitation in children with autistic disorder. J Child Adolesc Psychopharmacol. 1997;7:9–15.
   PubMed Web of Science ®Google Scholar
• McDougle CJ, Naylor ST, Cohen DJ, et al. A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Arch Gen Psychiatry. 1996;53:1001–1008.
   PubMed Web of Science ®Google Scholar
• Hollander E, Soorya L, Chaplin W, et al. A double-blind placebo-controlled trial of fluoxetine for repetitive behaviors and global severity in adult autism spectrum disorders. Am J Psychiatry. 2012;169:292–299.
   PubMed Web of Science ®Google Scholar
• McDougle CJ, Kresch LE, Posey DJ. Repetitive thoughts and behavior in pervasive developmental disorders: treatment with serotonin reuptake inhibitors. J Autism Dev Disord. 2000;30:427–35.
   PubMed Web of Science ®Google Scholar
• Hollander E, Phillips A, Chaplin W, et al. A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism. Neuropsychopharmacology. 2005;30:582–589.
   PubMed Web of Science ®Google Scholar
• King BH, Hollander E, Sikich L, et al. Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autism. Arch Gen Psychiatry. 2009;66:583–90.
   PubMed Web of Science ®Google Scholar
• Autism Speaks. Autism Speaks announces results reported for the Study of Fluoxetine in Autism (SOFIA): first industry-sponsored trial for the Autism Clinical Trials Network (ACTN) [Press release]. 2009 Feb 18. Available from: http://www.autismspeaks.org/about-us/press-releases/autism-speaks-announces-results- reported-study-fluoxetine-autism-sofia
   Google Scholar
• Brasic JR, Barnett JY, Kaplan D, et al. Clomipramine ameliorates adventitious movements and compulsions in prepubertal boys with autistic disorder and severe mental retardation. Neurology. 1994;44:1309–1312.
   PubMed Web of Science ®Google Scholar
• Brodkin ES, McDougle CJ, Naylor ST, et al. Clomipramine in adults with pervasive developmental disorders: a prospective open-label investigation. J Child Adolesc Psychopharmacol. 1997;7:109–121.
   PubMed Web of Science ®Google Scholar
• McDougle CJ, Price LH, Volkmar FR, et al. Clomipramine in autism: preliminary evidence of efficacy. J Am Acad Child Adolesc Psychiatry. 1992;31:746–750.
   PubMed Web of Science ®Google Scholar
• Gordon CT, Rapoport JL, Hamburger SD, et al. Differential response of seven subjects with autistic disorder to clomipramine and desipramine. Am J Psychiatry. 1992;149:363–366.
   PubMed Web of Science ®Google Scholar
• Brasic JR, Barnett JY, Sheitman BB, et al. Adverse effects of clomipramine. J Am Acad Child Adolesc Psychiatry. 1997;36:1165–1166.
   PubMed Web of Science ®Google Scholar
• Sanchez LE, Campbell M, Small AM, et al. A pilot study of clomipramine in young autistic children. J Am Acad Child Adolesc Psychiatry. 1996;35:537–544.
   PubMed Web of Science ®Google Scholar
• Brahm NC, Fast GA, Brown RC. Buspirone for autistic disorder in a woman with an intellectual disability. Ann Pharmacother. 2008;42:131–137.
   PubMed Web of Science ®Google Scholar
• Buitelaar JK, van der Gaag RJ, van der Hoeven J. Buspirone in the management of anxiety and irritability in children with pervasive developmental disorders: results of an open-label study. J Clin Psychiatry. 1998;59:56–59.
   PubMed Web of Science ®Google Scholar
• McCormick LH. Treatment with buspirone in a patient with autism. Arch Fam Med. 1997;6:368–370.
   PubMedGoogle Scholar
• Realmuto GM, August GJ, Garfinkel BD. Clinical effect of buspirone in autistic children. J Clin Psychopharmacol. 1989;9:122–125.
   PubMed Web of Science ®Google Scholar
• Posey DJ, Guenin KD, Kohn AE, et al. A naturalistic open-label study of mirtazapine in autistic and other pervasive developmental disorders. J Child Adolesc Psychopharmacol. 2001;11:267–277.
   PubMed Web of Science ®Google Scholar
• Simonoff E, Pickles A, Charman T, et al. Psychiatric disorders in children with autism spectrum disorders: prevalence, comorbidity, and associated factors in a population-derived sample. J Am Acad Child Adolesc Psychiatry. 2008;47:921–929.
   PubMed Web of Science ®Google Scholar
• Aman MG. Stimulant drugs in the developmental disabilities revisited. J Dev Phys Disabil. 1996;4:347–366.
   Web of Science ®Google Scholar
• Campbell M, Small AM, Hollander CS, et al. A controlled crossover study of triiodothyronine in autistic children. J Autism Child Schizophr. 1978;8:371–381.
   PubMedGoogle Scholar
• Stigler KA, Desmond LA, Posey DJ, et al. A naturalistic retrospective analysis of psychostimulants in pervasive developmental disorders. J Child Adolesc Psychopharmacol. 2004;14:49–56.
   PubMed Web of Science ®Google Scholar
• Birmaher B, Quintana H, Greenhill LL. Methylphenidate treatment of hyperactive autistic children. J Am Acad Child Adolesc Psychiatry. 1988;27:248–251.
   PubMed Web of Science ®Google Scholar
• Geller B, Guttmacher LB, Bleeg M. Coexistence of childhood onset pervasive developmental disorder and attention deficit disorder with hyperactivity. Am J Psychiatry. 1981;138:388–389.
   PubMed Web of Science ®Google Scholar
• Hoshino Y, Kumashiro H, Kaneko M, et al. The effects of methylphenidate on early infantile autism and its relation to serum serotonin levels. Folia Psychiatr Neurol Jpn. 1977;31:605–614.
   PubMedGoogle Scholar
• Strayhorn JM Jr, Rapp N, Donina W, et al. Randomized trial of methylphenidate for an autistic child. J Am Acad Child Adolesc Psychiatry. 1988;27:244–247.
   PubMed Web of Science ®Google Scholar
• Vitriol C, Farber B. Stimulant medication in certain childhood disorders. Am J Psychiatry. 1981;138:1517–1518.
   PubMed Web of Science ®Google Scholar
• Quintana H, Birmaher B, Stedge D, et al. Use of methylphenidate in the treatment of children with autistic disorder. J Autism Dev Disord. 1995;25:283–294.
   PubMed Web of Science ®Google Scholar
• Handen BL, Johnson CR, Lubetsky M. Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder. J Autism Dev Disord. 2000;30:245–55.
   PubMed Web of Science ®Google Scholar
• Research Units on Pediatric Psychopharmacology Autism Network. Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. Arch Gen Psychiatry. 2005;62:1266–1274.
   PubMed Web of Science ®Google Scholar
• Greenhill LL, Swanson JM, Vitiello B, et al. Impairment and deportment responses to different methylphenidate doses in children with ADHD: the MTA titration trial. J Am Acad Child Adolesc Psychiatry. 2001;40:180–187.
   PubMed Web of Science ®Google Scholar
• Ghuman JK, Aman MG, Lecavalier L, et al. Randomized, placebo-controlled, crossover study of methylphenidate for attention-deficit/hyperactivity disorder symptoms in preschoolers with developmental disorders. J Child Adolesc Psychopharmacol. 2009;19:329–339.
   PubMed Web of Science ®Google Scholar
• King BH, Lord C. Is schizophrenia on the autism spectrum? Brain Res. 2011;1380:34–41.
   PubMed Web of Science ®Google Scholar
• Biederman J, Melmed RD, Patel A, et al. A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics. 2008;121:e73–84.
   Google Scholar
• Connor DF, Findling RL, Kollins SH, et al. Effects of guanfacine extended release on oppositional symptoms in children aged 6–12 years with attention-deficit hyperactivity disorder and oppositional symptoms: a randomized, double-blind, placebo-controlled trial. CNS Drugs. 2010;24:755–768.
   PubMed Web of Science ®Google Scholar
• Sallee FR, McGough J, Wigal T, et al. Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: a placebo-controlled trial. J Am Acad Child Adolesc Psychiatry. 2009;48:155–165.
   PubMed Web of Science ®Google Scholar
• Connor DF, Barkley RA, Davis HT. A pilot study of methylphenidate, clonidine, or the combination in ADHD comorbid with aggressive oppositional defiant or conduct disorder. Clin Pediatr (Phila). 2000;39:15–25.
   PubMed Web of Science ®Google Scholar
• Jain R, Segal S, Kollins SH, et al. Clonidine extended-release tablets for pediatric patients with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2011;50:171–179.
   PubMed Web of Science ®Google Scholar
• Kollins SH, Jain R, Brams M, et al. Clonidine extended-release tablets as add-on therapy to psychostimulants in children and adolescents with ADHD. Pediatrics. 2011;127:e1406–13.
   PubMed Web of Science ®Google Scholar
• Ming X, Gordon E, Kang N, et al. Use of clonidine in children with autism spectrum disorders. Brain Dev. 2008;30:454–460.
   PubMed Web of Science ®Google Scholar
• Fankhauser MP, Karumanchi VC, German ML, et al. A double-blind, placebo-controlled study of the efficacy of transdermal clonidine in autism. J Clin Psychiatry. 1992;53:77–82.
   PubMed Web of Science ®Google Scholar
• Jaselskis CA, Cook EH Jr, Fletcher KE, et al. Clonidine treatment of hyperactive and impulsive children with autistic disorder. J Clin Psychopharmacol. 1992;12:322–7.
   PubMed Web of Science ®Google Scholar
• Posey DJ, Puntney JI, Sasher TM, et al. Guanfacine treatment of hyperactivity and inattention in pervasive developmental disorders: a retrospective analysis of 80 cases. J Child Adolesc Psychopharmacol. 2004;14:233–241.
   PubMed Web of Science ®Google Scholar
• Scahill L, Aman MG, McDougle CJ, et al. A prospective open trial of guanfacine in children with pervasive developmental disorders. J Child Adolesc Psychopharmacol. 2006;16:589–598.
   PubMed Web of Science ®Google Scholar
• Handen BL, Sahl R, Hardan AY. Guanfacine in children with autism and/or intellectual disabilities. J Dev Behav Pediatr. 2008;29:303–308.
   PubMed Web of Science ®Google Scholar
• Jou RJ, Handen BL, Hardan AY. Retrospective assessment of atomoxetine in children and adolescents with pervasive developmental disorders. J Child Adolesc Psychopharmacol. 2005;15:325–330.
   PubMed Web of Science ®Google Scholar
• Posey DJ, Wiegand RE, Wilkerson J, et al. Open-label atomoxetine for attention-deficit/hyperactivity disorder symptoms associated with high-functioning pervasive developmental disorders. J Child Adolesc Psychopharmacol. 2006;16:599–610.
   PubMed Web of Science ®Google Scholar
• Troost PW, Steenhuis MP, Tuynman-Qua HG, et al. Atomoxetine for attention-deficit/hyperactivity disorder symptoms in children with pervasive developmental disorders: a pilot study. J Child Adolesc Psychopharmacol. 2006;16:611–619.
   PubMed Web of Science ®Google Scholar
• Zeiner P, Gjevik E, Weidle B. Response to atomoxetine in boys with high-functioning autism spectrum disorders and attention deficit/hyperactivity disorder. Acta Paediatr. 2011;100:1258–1261.
   PubMed Web of Science ®Google Scholar
• Charnsil C. Efficacy of atomoxetine in children with severe autistic disorders and symptoms of ADHD: an open-label study. J Atten Disord. 2011;15:684–689.
   PubMed Web of Science ®Google Scholar
• Harfterkamp M, van de Loo-Neus G, Minderaa RB, et al. A randomized double-blind study of atomoxetine versus placebo for attention-deficit/hyperactivity disorder symptoms in children with autism spectrum disorder. J Am Acad Child Adolesc Psychiatry. 2012;51:733–741.
   PubMed Web of Science ®Google Scholar
• Arnold LE, Aman MG, Cook AM, et al. Atomoxetine for hyperactivity in autism spectrum disorders: placebo-controlled crossover pilot trial. J Am Acad Child Adolesc Psychiatry. 2006;45:1196–1205.
   PubMed Web of Science ®Google Scholar
• King BH, Wright DM, Handen BL, et al. Double-blind, placebo-controlled study of amantadine hydrochloride in the treatment of children with autistic disorder. J Am Acad Child Adolesc Psychiatry. 2001;40:658–665.
   PubMed Web of Science ®Google Scholar
• Lukas M, Neumann ID. Oxytocin and vasopressin in rodent behaviors related to social dysfunctions in autism spectrum disorders. Behav Brain Res. 2013;251:85–94.
   PubMed Web of Science ®Google Scholar
• Modahl C, Green L, Fein D, et al. Plasma oxytocin levels in autistic children. Biol Psychiatry. 1998;43:270–277.
   PubMed Web of Science ®Google Scholar
• Sauer C, Montag C, Worner C, et al. Effects of a common variant in the CD38 gene on social processing in an oxytocin challenge study: possible links to autism. Neuropsychopharmacology. 2012;37:1474–1482.
   PubMed Web of Science ®Google Scholar
• Domes G, Heinrichs M, Michel A, et al. Oxytocin improves “mind-reading” in humans. Biol Psychiatry. 2007;61:731–733.
   PubMed Web of Science ®Google Scholar
• Anagnostou E, Soorya L, Chaplin W, et al. Intranasal oxytocin versus placebo in the treatment of adults with autism spectrum disorders: a randomized controlled trial. Mol Autism. 2012;3:16.
   PubMed Web of Science ®Google Scholar
• Guastella AJ, Einfeld SL, Gray KM, et al. Intranasal oxytocin improves emotion recognition for youth with autism spectrum disorders. Biol Psychiatry. 2010;67:692–4.
   PubMed Web of Science ®Google Scholar
• Hollander E, Bartz J, Chaplin W, et al. Oxytocin increases retention of social cognition in autism. Biol Psychiatry. 2007;61:498–503.
   PubMed Web of Science ®Google Scholar
• Kosaka H, Munesue T, Ishitobi M, et al. Long-term oxytocin administration improves social behaviors in a girl with autistic disorder. BMC Psychiatry. 2012;12:110.
   PubMed Web of Science ®Google Scholar
• Auyeung B, Lombardo MV, Heinrichs M, et al. Oxytocin increases eye contact during a real-time, naturalistic social interaction in males with and without autism. Transl Psychiatry. 2015;5:e507.
   PubMed Web of Science ®Google Scholar
• Ring RH, Schechter LE, Leonard SK, et al. Receptor and behavioral pharmacology of WAY-267464, a non-peptide oxytocin receptor agonist. Neuropharmacology. 2010;58:69–77.
   PubMed Web of Science ®Google Scholar
• Scott MM, Deneris ES. Making and breaking serotonin neurons and autism. Int J Dev Neurosci. 2005;23:277–285.
   PubMed Web of Science ®Google Scholar
• Gabriels RL, Cuccaro ML, Hill DE, et al. Repetitive behaviors in autism: relationships with associated clinical features. Res Dev Disabil. 2005;26:169–181.
   PubMed Web of Science ®Google Scholar
• Brinkley J, Nations L, Abramson RK, et al. Factor analysis of the aberrant behavior checklist in individuals with autism spectrum disorders. J Autism Dev Disord. 2007;37:1949–1959.
   PubMed Web of Science ®Google Scholar